IMMUNITYBIO, INC. (IBRX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 20.70%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 20.70% | Share-based compensation / revenue. Period ending 2026-06-30. $34.31M ÷ $165.79M × 100 ≈ 20.70% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 165.79M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 34.31M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -251.80M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $165.79M | $34.31M | $-251.80M | (m) | (m) | 20.70% | (m) | (m) |
| 2026-03-31 | (m) | $140.98M | $35.44M | $-261.39M | (m) | (m) | 25.14% | (m) | (m) |
| 2025-12-31 | (m) | $113.29M | $36.81M | $-256.03M | $60.89M | (m) | 32.49% | -4.21× | Reported |
| 2025-09-30 | (m) | $82.56M | $37.10M | $-260.74M | $72.15M | (m) | 44.94% | -3.61× | Reported |
| 2025-06-30 | (m) | $56.60M | $35.71M | $-285.37M | $86.21M | (m) | 63.10% | -3.31× | Reported |
| 2025-03-31 | (m) | $31.22M | $35.70M | $-313.42M | $100.53M | (m) | 114.35% | -3.12× | Reported |
| 2024-12-31 | $190.14M | $14.74M | $34.43M | $-344.18M | $114.67M | 1289.55% | 233.52% | -3.00× | Reported |
| 2024-09-30 | $206.46M | $7.33M | $38.17M | $-360.17M | $120.72M | 2815.81% | 520.57% | -2.98× | Reported |
| 2024-06-30 | $204.41M | $1.31M | $45.13M | $-360.05M | $126.42M | 15627.98% | 3450.15% | -2.85× | Reported |
| 2024-03-31 | $206.45M | $302.00K | $46.55M | $-345.87M | $128.87M | 68361.92% | 15414.24% | -2.68× | Reported |
| 2023-12-31 | $232.37M | $622.00K | $49.16M | $-362.25M | $129.20M | 37357.88% | 7904.02% | -2.80× | Reported |
| 2023-09-30 | $238.91M | $556.00K | $45.74M | $-361.76M | $125.63M | 42969.60% | 8226.44% | -2.88× | Reported |
| 2023-06-30 | $262.12M | $592.00K | $41.92M | $-372.43M | $107.38M | 44277.20% | 7081.08% | -3.47× | Reported |
| 2023-03-31 | $272.04M | $586.00K | $41.03M | $-366.91M | $84.84M | 46422.35% | 7002.22% | -4.32× | Reported |
| 2022-12-31 | $248.15M | $240.00K | $40.18M | $-351.30M | $63.52M | 103395.42% | 16741.25% | -5.53× | Reported |
| 2022-09-30 | $241.82M | $557.00K | $41.01M | $-345.67M | $39.44M | 43415.62% | 7362.48% | -8.76× | Reported |
| 2022-06-30 | $219.49M | $505.00K | $44.22M | $-333.70M | $26.29M | 43463.37% | 8756.24% | -12.69× | Reported |
| 2022-03-31 | $210.21M | $809.00K | $51.91M | $-339.99M | $20.17M | 25983.68% | 6416.19% | -16.85× | Reported |
| 2021-12-31 | $195.96M | $934.00K | $57.18M | $-330.28M | $14.85M | 20980.51% | 6122.16% | -22.24× | Reported |
| 2021-09-30 | $187.56M | $397.00K | $47.67M | $-318.39M | (m) | 47244.58% | 12008.06% | (m) | (m) |
| 2021-06-30 | $174.06M | $482.00K | $34.55M | $-305.43M | (m) | 36111.20% | 7167.22% | (m) | (m) |
| 2021-03-31 | $153.26M | $579.00K | $17.00M | $-270.44M | (m) | 26469.95% | 2936.96% | (m) | (m) |
| 2020-12-31 | $64.48M | $111.00K | $2.14M | $-91.63M | (m) | 58092.79% | 1927.03% | (m) | (m) |
| 2020-09-30 | $56.23M | $99.00K | $1.95M | $-76.85M | (m) | 56798.99% | 1968.69% | (m) | (m) |
| 2020-06-30 | $51.00M | $43.00K | $1.51M | $-70.99M | (m) | 118602.33% | 3523.26% | (m) | (m) |
| 2020-03-31 | $50.42M | $59.00K | $1.72M | $-68.06M | (m) | 85459.32% | 2916.95% | (m) | (m) |
| 2019-12-31 | $49.78M | $43.00K | $2.63M | $-67.81M | (m) | 115779.07% | 6109.30% | (m) | (m) |
| 2019-09-30 | $50.26M | $41.00K | $3.56M | $-69.42M | (m) | 122587.80% | 8675.61% | (m) | (m) |
| 2019-06-30 | $52.77M | $60.00K | $7.25M | $-77.46M | (m) | 87946.67% | 12080.00% | (m) | (m) |
| 2019-03-31 | $54.33M | $47.00K | $15.66M | $-88.44M | (m) | 115585.11% | 33319.15% | (m) | (m) |
| 2018-12-31 | $55.72M | $47.00K | $23.38M | $-98.39M | (m) | 118548.94% | 49748.94% | (m) | (m) |
| 2018-09-30 | $55.26M | $52.00K | $30.86M | $-106.06M | (m) | 106267.31% | 59344.23% | (m) | (m) |
| 2018-06-30 | $51.77M | $29.00K | $35.60M | $-106.40M | (m) | 178513.79% | 122775.86% | (m) | (m) |
| 2018-03-31 | $46.79M | $39.00K | $36.05M | $-101.94M | $614.00K | 119966.67% | 92441.03% | -166.03× | Reported |
| 2017-12-31 | $42.04M | $45.00K | $37.00M | $-99.12M | $618.00K | 93431.11% | 82215.56% | -160.39× | Reported |
| 2017-09-30 | $39.47M | $47.00K | $39.38M | $-98.87M | $621.00K | 83974.47% | 83785.11% | -159.21× | Reported |
| 2017-06-30 | $36.76M | $51.00K | $49.33M | $-107.20M | $257.00K | 72084.31% | 96733.33% | -417.13× | Reported |
| 2017-03-31 | $33.45M | $49.00K | $63.31M | $-118.35M | $103.00K | 68257.14% | 129200.00% | -1149.01× | Reported |
| 2016-12-31 | $29.15M | $44.00K | $73.85M | $-124.50M | $66.00K | 66256.82% | 167845.45% | -1886.36× | Reported |
| 2016-09-30 | $23.78M | $44.00K | $83.99M | (m) | (m) | 54040.91% | 190890.91% | (m) | (m) |
| 2016-06-30 | $20.10M | $43.00K | $104.30M | (m) | (m) | 46746.51% | 242562.79% | (m) | (m) |
| 2016-03-31 | $15.78M | $122.00K | $207.23M | (m) | (m) | 12930.33% | 169863.11% | (m) | (m) |
| 2015-12-31 | $11.43M | $236.00K | $211.22M | (m) | (m) | 4844.92% | 89500.42% | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $475.00K | (m) | $-36.85M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $1.59M | $641.00K | $789.00K | $-5.58M | $471.00K | 248.83% | 123.09% | -11.84× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $446.00K | $600.00K | $884.00K | (m) | $463.00K | 74.33% | 147.33% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |